Immunological and antitumor responses to HPV-targeted therapeutic vaccines in preclinical models of head and neck cancer: a systematic review. | ClinicLens
Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is increasingly prevalent and accounts for 22-70% of HNSCCs depending on the region. Although prophylactic HPV vaccines were approved in the early 2000s to prevent HPV infection and oncogenesis, t
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.